Clinical Trials

    Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer (INTEGRAL)

    Investigator: Polly Niravath

    Study Coordinator: Kelsey Banaglorioso

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT04095689

    Phone: 346.238.5740

    Protocol Number: PRO00028602

    Description


    The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative breast cancer (TNBC).